Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Transplant. Dec 18, 2025; 15(4): 105905
Published online Dec 18, 2025. doi: 10.5500/wjt.v15.i4.105905
Published online Dec 18, 2025. doi: 10.5500/wjt.v15.i4.105905
Toxic agranulocytosis following nitazoxanide treatment for norovirus diarrhea in a kidney transplant recipient: A case report and review of literature
Dorian Grépilloux, Corentin Guéneau, Jules Weinhard, Rémi Richaud, Eloi Chevallier, Thomas Jouve, Julien Dusserre, Lionel Rostaing, Department of Nephrology, Hemodialysis, Apheresis, and Kidney Transplantation, Grenoble University Hospital, Grenoble 38043, France
Thomas Jouve, Lionel Rostaing, Department of Medicine, Université Grenobles-Alpes, Grenoble 38000, France
Author contributions: Jouve T contributed to conceptualization, methodology and validation; Weinhard J and Richaud R contributed to investigation; Grépilloux D, Guéneau C, and Dusserre J contributed to writing and original draft preparation; Rostaing L contributed to writing, review and editing; Chevallier E contributed to supervision.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: All authors declare no conflicts of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Lionel Rostaing, MD, PhD, Professor, Department of Nephrology, Hemodialysis, Apheresis, and Kidney Transplantation, Grenoble University Hospital, CS10217, Grenoble 38043, France. lrostaing@chu-grenoble.fr
Received: February 21, 2025
Revised: April 24, 2025
Accepted: September 24, 2025
Published online: December 18, 2025
Processing time: 271 Days and 12.4 Hours
Revised: April 24, 2025
Accepted: September 24, 2025
Published online: December 18, 2025
Processing time: 271 Days and 12.4 Hours
Core Tip
Core Tip: Nitazoxanide is a thiazolide compound. The Food and Drug Administration has approved it for the treatment of Giardia intestinalis and Cryptosporidium parvum infections in immunocompromised patients aged 12 years or older. In immunocompromised patients, nitazoxanide use for chronic Norovirus diarrhea has been reported and appears promising, including in solid organ transplant recipients. However, the drug is not yet approved for this indication. We herein report on a patient for which nitazoxanide induced a dose-dependent toxic agranulocytosis.